Renascience Inc.

Renascience Inc. develops and sells pharmaceuticals, medical devices, and artificial intelligence (AI)-powered programmed medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angio-sarcoma, coronavirus lung injury, and interstitial lung disease associated with systemic scleroderma; RS5441, PAI-1 inhibitor for the treatment of alopecia disease that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder and menopausal disorder, which is in phase 1 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence-based medical solutions; pancreatic cancer; anti-aging and longevity oral drugs (senolytics); topical medications for male pattern baldness and age-related hair loss; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Sendai, Japan.